Literature DB >> 2328298

Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man.

L Borgström1, B Kågedal.   

Abstract

The pharmacokinetics after oral administration of 200, 600 or 1200 mg of N-acetylcysteine (NAC) were studied in 10 healthy subjects. Normalized maximal plasma concentration was significantly higher after a 600 mg dose than after a 200 mg dose. Bioavailability of NAC significantly increased with increasing dose. Time for maximal plasma concentration also increased with increasing dose. The observations can be explained by a capacity-limited presystemic elimination of NAC. In an extension of the study, 600 mg of NAC was given twice a day for 5 days and the plasma concentrations were followed after the morning dose on day 6. No differences in the pharmacokinetic parameters were observed in comparison with the single 600 mg dose. This indicates that the beneficial clinical effects observed after repeated dosing can not be ascribed to an accumulation of NAC in plasma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2328298     DOI: 10.1002/bdd.2510110205

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  13 in total

1.  Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease.

Authors:  Thomas D Nolin; Rosemary Ouseph; Jonathan Himmelfarb; M Elizabeth McMenamin; Richard A Ward
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

2.  N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data.

Authors:  Peng-Chan Lin; Ming-Yang Lee; Wei-Shu Wang; Chueh-Chuan Yen; Ta-Chung Chao; Liang-Tsai Hsiao; Muh-Hwa Yang; Po-Min Chen; Kon-Ping Lin; Tzeon-Jye Chiou
Journal:  Support Care Cancer       Date:  2006-02-01       Impact factor: 3.603

Review 3.  N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.

Authors:  Olivia Dean; Frank Giorlando; Michael Berk
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

4.  A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage.

Authors:  Giulia Lizzo; Eugenia Migliavacca; Daniela Lamers; Adrien Frézal; John Corthesy; Gerard Vinyes-Parès; Nabil Bosco; Leonidas G Karagounis; Ulrike Hövelmann; Tim Heise; Maximilian von Eynatten; Philipp Gut
Journal:  Front Aging       Date:  2022-03-07

Review 5.  Environmental toxicity, redox signaling and lung inflammation: the role of glutathione.

Authors:  Saibal K Biswas; Irfan Rahman
Journal:  Mol Aspects Med       Date:  2008-08-08

Review 6.  Antioxidant therapeutic advances in COPD.

Authors:  Irfan Rahman
Journal:  Ther Adv Respir Dis       Date:  2008-12       Impact factor: 4.031

Review 7.  Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.

Authors:  Hoi Nam Tse; Cee Zhung Steven Tseng
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-08-06

8.  Evidence of a Redox-Dependent Regulation of Immune Responses to Exercise-Induced Inflammation.

Authors:  Alexandra Sakelliou; Ioannis G Fatouros; Ioannis Athanailidis; Dimitrios Tsoukas; Athanasios Chatzinikolaou; Dimitris Draganidis; Athanasios Z Jamurtas; Christina Liacos; Ioannis Papassotiriou; Dimitrios Mandalidis; Kimon Stamatelopoulos; Meletios A Dimopoulos; Asimina Mitrakou
Journal:  Oxid Med Cell Longev       Date:  2016-11-15       Impact factor: 6.543

Review 9.  Role of N-acetylcysteine in the management of COPD.

Authors:  Anna M Sadowska; J Verbraecken; K Darquennes; W A De Backer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Glutamate homeostasis and dopamine signaling: Implications for psychostimulant addiction behavior.

Authors:  Kathryn D Fischer; Lori A Knackstedt; Paul A Rosenberg
Journal:  Neurochem Int       Date:  2020-11-05       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.